Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (NASDAQ: PODD) is a Massachusetts-based medical device company known for its Omnipod tubeless insulin pump platform, which is designed to simplify life for people with diabetes. The Insulet news feed on Stock Titan aggregates company announcements, earnings updates, product milestones, and strategic disclosures that shape the PODD stock narrative and the evolution of automated insulin delivery.
Investors and observers can follow news on the Omnipod Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors to automate insulin dosing without multiple daily injections or fingersticks. Company releases highlight regulatory clearances, such as FDA 510(k) decisions for Omnipod 5 algorithm enhancements, as well as technology demonstrations at events like the Consumer Electronics Show, where Insulet presents its vision for “liveable technology” in connected health.
The PODD news stream also covers quarterly and annual financial results, long-range financial outlooks, and Investor Day presentations in which Insulet outlines its growth strategy in automated insulin delivery markets. Additional updates include sustainability initiatives like the expansion of the U.S. Pod recycling program, collaborations such as the Omnipod Mango color partnership with Pantone, and governance developments including executive and board appointments.
By reviewing Insulet news on this page, readers can track how the company’s Omnipod platform, innovation roadmap, financial performance, and corporate actions intersect. Bookmark this feed to monitor new product features, regulatory developments, strategic events, and other disclosures that may be relevant to understanding PODD as both a medical technology business and a publicly traded stock.
Insulet Corporation (NASDAQ: PODD) reported strong financial results for Q3 2020, with revenue reaching $234.0 million, a 21.8% increase from the previous year, exceeding guidance of 13% to 15%. Total Omnipod revenue was $212.1 million, a 19.7% increase. The company achieved a gross margin of 64.9% and net income of $11.6 million, significantly higher than $0.8 million in Q3 2019. Insulet raised its full-year revenue outlook to 20% to 21% growth, with plans for the commercial launch of Omnipod 5 in early 2021.
Insulet Corporation (NASDAQ: PODD) announces its initiatives for Diabetes Awareness Month in November. The company aims to highlight inspiring stories of individuals with diabetes through a campaign called “YESvember.” It will also honor its 20th anniversary by ringing the Nasdaq closing bell on November 9, 2023. Insulet is committed to supporting diabetes research by participating in the JDRF One Walk to raise funds and awareness. The events focus on empowering those with diabetes and acknowledging healthcare providers in their efforts.
Summary not available.
Insulet Corporation (NASDAQ: PODD) announced the appointment of Dr. Wayne A. I. Frederick to its Board of Directors, effective immediately. Dr. Frederick, who is the president of Howard University, brings extensive experience in healthcare disparities, surgery, and medical education. He will also serve on the Board's Audit Committee. The company’s chairman expressed confidence that Dr. Frederick's expertise will significantly benefit Insulet’s global strategic growth initiatives, particularly in advancing its tubeless insulin pump technology.
Insulet Corporation (NASDAQ: PODD) will release its third-quarter financial results on November 4, 2020, after market close. The announcement will be followed by a conference call at 4:30 p.m. ET. Insulet is recognized for its Omnipod Insulin Management System, a tubeless insulin delivery solution designed for diabetes management. The company continues to innovate with its product platform, enhancing the ease of insulin delivery for users. Interested investors can access the live call through the Investor Relations section of Insulet's website.